摘要
First-line treatment with encorafenib, cetuximab, and mFOLFOX6 significantly improved survival outcomes in patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), according to phase III data from the BREAKWATER trial published in The New England Journal of Medicine (2025; doi.org/10.1056/NEJMoa2501912). BRAF V600E mutations are present in approximately 8% to 12% of metastatic colorectal cancers, and are associated with a distinctly aggressive clinical phenotype. These tumors exhibit poor responses to standard chemotherapy and a markedly worse prognosis than their BRAF wild-type counterparts. Historically, median overall survival (OS) for patients with BRAF-mutated mCRC has hovered around 11 months with chemotherapy, compared to 24 months for those with wild-type disease. While the combination of encorafenib and cetuximab demonstrated efficacy in previously treated patients through the BEACON CRC trial, data supporting first-line use of BRAF- and EGFR-targeted therapy remained limited prior to BREAKWATER. The rationale for combining these targeted agents with chemotherapy emerged from mechanistic insights showing that monotherapy with BRAF inhibitors triggers EGFR-mediated pathway reactivation in CRC, blunting treatment responses. BREAKWATER was a global, open-label, phase III trial enrolling 637 adults with previously untreated, BRAF V600E–mutated mCRC. Participants were randomized to receive: encorafenib plus cetuximab (EC); EC combined with mFOLFOX6 chemotherapy (EC+mFOLFOX6); or standard investigator-selected chemotherapy (mFOLFOX6, CAPOX, or FOLFOXIRI) with or without bevacizumab. Following a protocol amendment, the EC-only arm was closed to focus analyses on EC+mFOLFOX6 vs. standard care. The two primary endpoints were objective response and progression-free survival (PFS) assessed by blinded central review. OS was a key secondary endpoint. Patients were stratified by ECOG performance status and geographic region. Efficacy Outcomes EC+mFOLFOX6 significantly improved median PFS to 12.8 months (95% CI: 11.2-15.9), compared with 7.1 months (95% CI: 6.8-8.5) for standard care (HR: 0.53; 95% CI: 0.41-0.68; P<0.001). Kaplan-Meier curves showed early and sustained separation favoring the triplet regimen. An updated interim analysis revealed a doubling in median OS with EC+mFOLFOX6 (30.3 months; 95% CI: 21.7-not estimable) vs. standard care (15.1 months; 95% CI: 13.7-17.7) (HR: 0.49; 95% CI: 0.38-0.63; P<0.001). Estimated 2-year survival rates were 52% with EC+mFOLFOX6 and 29% with standard care. Confirmed objective response rates were 65.7% with EC+mFOLFOX6 compared to 37.4% with standard care. Median time to response was just 7 weeks in both arms, but the duration of response was longer in the EC+mFOLFOX6 group (13.9 vs. 10.8 months). Subgroup analyses consistently favored EC+mFOLFOX6 across age groups, sex, tumor sidedness, and extent of metastases. While EC+mFOLFOX6 was associated with higher rates of grade ≥3 adverse events (81.5%) compared to standard care (66.8%), the toxicities were largely manageable with dose adjustments and supportive care. Common high-grade events included neutropenia (19%), anemia (15.1%), and neuropathy (6.9%). Serious adverse events occurred in 46.1% of EC+mFOLFOX6 recipients vs. 38.9% with standard care. Permanent discontinuation of any agent occurred in 26.7% and 17.5% of patients, respectively. Despite the intensity of the triplet regimen, the safety profile was consistent with expectations for the component agents. EC+mFOLFOX6's risk-benefit profile was considered favorable given its survival advantage. To gain additional insights into the study, Oncology Times spoke with senior author Scott Kopetz, MD, PhD, FACP, of The University of Texas MD Anderson Cancer Center, where he serves as Professor and Deputy Chair of GI Medical Oncology, Medical Director of TRACTION within the Division of Therapeutics Discovery, and Associate Vice President for Translational Integration. Oncology Times: How do you interpret the clinical significance of these findings, particularly the doubling of median overall survival? Kopetz: “The findings from BREAKWATER represent a new standard of care for patients with newly diagnosed metastatic colorectal cancer that is microsatellite stable (MSS) and with a BRAF V600E mutation. This is based on a doubling of median overall survival for EC+FOLFOX patients, compared to standard of care therapy (which included the option for cytotoxic doublets or triplets with or without bevacizumab and treatment with BRAF targeted therapy at second line and beyond).” Oncology Times: From your clinical experience, how manageable are the toxicities, and what strategies would you use to optimize tolerability in practice? Kopetz: “The overall rate of treatment emergent side effects varies by the duration of therapy, and EC+FOLFOX patients had a median PFS of 12.8 vs. 7.1 months in the SOC arm, with grade 3 or higher adverse event rate (without regard to attribution) of 81.5% vs. 66.8%, respectively. Importantly, the serious adverse events attributed to treatment was 19% for EC+FOLFOX compared to 21% for the standard of care arm. Side effects related to EC include acneiform rash, arthralgia, and anemia, which were rarely high grade and can be managed conservatively. Preventative strategies for rash management can follow that done for EGFR inhibitor combinations, and arthralgias commonly can be adequately treated with over-the-counter anti-inflammatory agents without requiring dose interruptions or reductions.” Oncology Times: Benefits were consistent across subgroups, even high-risk patients. How might this affect your first-line therapy choice? Kopetz: “The subgroup analysis demonstrates that this activity is present in all evaluated subsets, and would be considered a new standard of care for all patients with newly diagnosed mCRC with MSS tumors with BRAF V600E mutation. For patients who are not candidates for FOLFOX therapy (for example, due to pre-existing neuropathy or recent adjuvant therapy with oxaliplatin-containing regimen), a subsequent cohort of EC+FOLFIRI vs. SOC will be reported out later in the year. For the MSI-High population with BRAF V600E, we anticipate reporting results from the SEAMARK study of pembrolizumab with or without encorafenib and cetuximab in the near future.” Dibash Kumar Das is a contributing writer.